DK EN
Enter at least 3 characters
news.png
HOME > Medier
print.png
 
Ny EU kommissionsgodkendelse af behandling for Fabrys sygdom
Pressemeddelelse, Stockholm den 11. marts 2026   ”Ny EU kommissionsgodkendelse af behandling for...
btnaree.png
1/7
Inhalator med op til 90% mindre CO2-udledning: Chiesi...
2/7
Chiesis nye generation af inhalationsdevice, pMDI, der...
3/7
ARCHIVE NYHEDER AND PRESSEMEDDELELSER
October 2024
30 October
Ny patienthjemmeside om KOL
btnboxnews.png
October 2023
18 October
Chiesi and Karolinska Institutet (KI) Forge Strategic Research Alliance to Advance Precision...
btnboxnews.png
Juny 2020
08 June
Chiesi Nordics supports employees, patients and caregivers during the Covid-19 pandemic
btnboxnews.png
April 2020
28 April
Rengøring af AeroChamber Flow-Vu
btnboxnews.png
March 2020
30 March
Chiesi Group increases support measures and announces new funds for employees, patients and...
btnboxnews.png
Febrary 2020
06 February
Chiesi Group Announces Establishment of New Global Rare Diseases Division
btnboxnews.png
Dicember 2019
04 December
Chiesi investerar 350 miljoner EURO i den första koldioxidsnåla sprayinhalatorn för astma och KOL
btnboxnews.png
© 2026 Chiesi Pharma AB
Klara Norra kyrkogata 34, 111 22 Stockholm
Telefon +46 8 753 35 20
E-post infonordic@chiesi.com

CHIESI PÅ INTERNETTET
mappa.png